BiologicsFreedonia Group Inc
September 1, 2011
316 Pages - SKU: FG6586638
Additional InformationPRESS RELEASE
US Demand for Biologics to Reach $102 Billion in 2015
US demand for biologics is expected to grow 6.5 percent per year to $102 billion in 2015, driven by dramatic shifts in production technology and an expansion in the number of targeted diseases. New biologics are being developed for the treatment of cancer, diabetes and other serious medical conditions, many of which are seeing their incidence rise in the US population. While growth in market value will slow from the double-digit advances registered during the past decade, this is primarily a function of restrained pricing which will mask to some extent continued robust gains in market penetration. The introduction of biosimilars into the US market is expected to contribute to both of these trends. These and other trends are presented in Biologics, a new study from The Freedonia Group, Inc., a Cleveland-based industry research firm.
Biologics such as insulin, vaccines and various blood products have been available for many years. However, the more recent introduction of recombinant DNA technology has allowed manufacturers to develop a wide range of new products with very specific applications. Of more than 40 brand-named monoclonal antibodies currently available in the US, 26 have received FDA approval since 2000, and 15 of the 26 since 2005. These products have quickly established themselves as effective therapies for many forms of cancer, macular degeneration, rheumatoid arthritis and other diseases. New antibodies are under intensive investigation, and are expected to be introduced to market during the forecast period.
A growing global market for biosimilars (also known as follow-on biologics) is gaining momentum in response to the expiration of patents for a number of key biologics and consumer demand to reduce treatment costs. Europe has led the global regulatory process to make biosimilars available but to date US approvals have lagged behind those in the international community. The FDA has allowed only a few biosimilars for sale in the US, generally following procedures for small molecule generics. However, the FDA has announced plans to release new regulatory guidelines by the end of 2011 which will clarify the approval process for follow-on biologics. Once biosimilars can be approved for US sale, they are expected to make lower-cost biologic treatments more widely available, presenting a challenge to some longstanding proprietary products.
More United States Biopharmaceuticals reports
U.S. Payer and Prescriber Attitudes Toward Novel Oral, Topical, and Biologic Emerging Agents in the Psoriasis Market: Implications for Market Access by Decision Resources
The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor-alpha (TNF-a) inhibitors ...
How Will U.S. Payers and Prescribers Determine the Success of New Biologics and Oral Entrants and Currently Marketed Biologics in Psoriatic Arthritis and Axial Spondyloarthritis? by Decision Resources
This U.S. Physician & Payer Forum report explores payer and physician dynamics that affect prescribing practices for psoriatic arthritis (PsA) and axial spondyloarthritis ...
Spinal Devices and Biologics Market in the US 2011-2015 by Infiniti Research Limited
TechNavio's analysts forecast the Spinal Devices and Biologics market in the US to grow at a CAGR of 1.2 percent over the period 2011-2015. One ...
Biosimilars Advisory Service: U.S. AND E.U. Payer Perspectives by Decision ResourcesSee all reports like this >>
The Biosimilars Advisory Service from BioTrends provides insight and analysis that’s vital to successful business planning in the rapidly evolving biosimilars space. Quarterly webinars detailing ...
More United States reports
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
The 2013-2018 Outlook for Indian Breads in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for Indian breads across the states and cities of the United States. Latent demand (in millions of ...
D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.See all reports like this >>
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
We can help you find what you need. Call us or write us:
Need help in your search?
- Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion
- Biologic Therapeutic Drugs: Technologies and Global Markets
- Biologic Imaging Reagents: Technologies and Global Markets
- Innovation in the Prefilled Syringe Market - Biologics and Autoinjection Devices Shaping Future R&D Trends
- How Will the Launches of Oral Immunomodulators and Biosimilars Shape the EU5 Prescribing and Reimbursement Landscape for Current and Emerging Biologics in Rheumatoid Arthritis?